X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).
Lead Product(s): CAN-3110,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CAN-3110
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Candel Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 21, 2024
Details:
Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII[2] polio containment in Solna, Sweden, using Batavia’s process.
Lead Product(s): Inactivated polio vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Valneva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 16, 2020
Details:
By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral disease threats.
Lead Product(s): VSV∆G-SARS-CoV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: IAVI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
